2026-04-13T05:02:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/114772025-10-24T10:16:56Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Köhler, Bruno author Bes, Marta author Chan, Henry Lik Yuen author Sukeepaisarnjaroen, Wattana author Esteban Mur, Juan Ignacio author Piratvisuth, Teerha author 2024-05-21T09:11:55Z 2024-05-21T09:11:55Z 2024-06 Cholangiocarcinoma; Biomarkers; Liquid biopsy Colangiocarcinoma; Biomarcadors; Biòpsia líquida Colangiocarcinoma; Biomarcadores; Biopsia líquida Introduction Diagnosis of cholangiocarcinoma (CCA) can be challenging due to unclear imaging criteria and difficulty obtaining adequate tissue biopsy. Although serum cancer antigen 19-9 and carcinoembryonic antigen have been proposed as potential diagnostic aids, their use remains limited by insufficient sensitivity and specificity. This exploratory analysis aimed to identify individual- and combinations of serum biomarkers to distinguish CCA from hepatocellular carcinoma (HCC) and chronic liver disease (CLD) controls using samples from a published study. Methods This prospective, multicenter, case-control study included patients aged ≥18 years at high-risk of HCC. Serum and ethylene diamine tetraacetic acid-plasma samples were collected prior to any treatment and confirmed diagnosis of HCC or CCA. Fourteen biomarkers (measured by electrochemiluminescence immunoassays or enzyme-linked immunosorbent assays) were subjected to univariate analysis and 13 included in a multivariate analysis (per selected combinations and exhaustive search). Results Overall, 55 CCA, 306 HCC, and 733 CLD control samples were analyzed. For distinguishing CCA from HCC, alpha-fetoprotein and matrix metalloproteinase-2 (MMP-2) showed the best individual performance (area under the curve (AUC) 86.6% and 84.4%, respectively); tissue inhibitor of metalloproteinase-1 (TIMP-1) was most able to distinguish CCA from CLD (AUC 94.5%) and from HCC  +  CLD (AUC 88.6%). The combination of MMP-2 and TIMP-1 was the best-performing two-marker panel, with AUC >90% for all comparisons. Conclusion MMP-2 and TIMP-1 are promising biomarkers that could support differential diagnosis of CCA. Incorporating these assays into the diagnostic algorithm could provide additional diagnostic information in a non-invasive, rapid manner, and could supplement existing diagnostic methods. This analysis was funded by Roche Diagnostics GmbH (Germany). Editorial support was provided by Steph Carter and Jade Drummond of inScience Communications, Springer Healthcare Ltd, UK, and was funded by Roche Diagnostics International Ltd (Rotkreuz, Switzerland). http://hdl.handle.net/11351/11477 Fetge - Malalties - Diagnòstic Conductes biliars - Càncer - Diagnòstic Diagnòstic diferencial DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Cholangiocarcinoma Other subheadings::Other subheadings::/diagnosis CHEMICALS AND DRUGS::Biological Factors::Biomarkers ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnosis, Differential ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma::colangiocarcinoma Otros calificadores::Otros calificadores::/diagnóstico COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico diferencial A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis